Prospective Grant of Exclusive License: Regulatory Approved Clinical Diagnostics for Anti-HPV16 L1 Serum Antibody Detection in HPV Vaccine Recipients, 9582 [E8-3162]
Download as PDF
9582
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: February 11, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–3165 Filed 2–20–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Regulatory Approved Clinical
Diagnostics for Anti-HPV16 L1 Serum
Antibody Detection in HPV Vaccine
Recipients
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
pwalker on PROD1PC71 with NOTICES
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
worldwide license to practice the
invention embodied in HHS Ref. No. E–
253–1993/0 and certain foreign rights
under HHS Ref. No. E–166–1992
including U.S. Patent 5,437,951, U.S.
Patent 5,985,610, U.S. Patent 5,871,998,
U.S. Patent 5,716,620, U.S. Patent
5,744,142, U.S. Patent 5,756,284, U.S.
Patent 5,709,996, U.S. Patent
Application 09/316,487, U.S. Patent
Application 10/371,846, International
Patent Application PCT/US93/08342,
European Patent Application
93921353.4, European Patent
Application 040104531.1, European
Patent Application 040783235,
Australian Patent 683220, Australian
Patent Application 2004203609,
Canadian Patent No. 2,143,845, Japanese
Patent Applications 1994–507481,
Japanese Patent Applications 2001–
101791 and continuation and divisional
patents and patent applications thereof,
entitled ‘‘Self-Assembling Recombinant
Papillomavirus HPV16 Capsid
Proteins,’’ to Biotrin International, Ltd.,
a limited liability company formed
under the laws of the European Union
and the Republic of Ireland. The United
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
States of America is the assignee of the
patent rights of the above inventions.
The contemplated exclusive license
may be granted in the field of regulatory
approved clinical diagnostics for serum
anti-HPV16 L1 antibody detection in
HPV vaccine recipients.
DATE: Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before April 21, 2008 will be
considered.
ADDRESSES: Requests for a copy of the
patent applications, inquiries,
comments and other materials relating
to the contemplated license should be
directed to: Michael A. Shmilovich,
Esq., Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–5019; Facsimile: (301) 402–
0220; E-mail: shmilovm@mail.nih.gov.
A signed confidentiality nondisclosure
agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION: The patent
applications intended for licensure
disclose and/or cover the following:
E–253–1993 and E–166–1992, ‘‘SelfAssembling Recombinant
Papillomavirus Capsid Proteins of
HPV16,’’ Lowy et al.
Recombinant human papillomavirus
16 capsid proteins that are capable of
self-assembly into capsomer structures
and viral capsids that comprise
conformational antigenic epitopes. The
capsomer structures and viral capsids,
consisting of the capsid proteins that are
expression products of a bovine,
monkey or human papillomavirus L1
conformational coding sequence
proteins, can be prepared for use in
ELISA or cell-based immunoassays for
detecting the level of serum antibody in
recipients of a vaccine against HPV16.
The self-assembling capsid proteins can
also be used as elements of diagnostic
immunoassay procedures for
papillomavirus infection.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within sixty (60) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: February 14, 2008.
David Sadowski,
Deputy Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E8–3162 Filed 2–20–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service
[FWS–R9–MB–2008–N0031]
Wildlife and Sport Fish Restoration
Program
Fish and Wildlife Service,
Interior.
ACTION: Notice of receipt of priority list.
AGENCY:
SUMMARY: We, the U.S. Fish and
Wildlife Service (FWS), announce the
FY 2008 priority list of wildlife and
sport fish conservation projects from the
Association of Fish and Wildlife
Agencies (AFWA). As required by the
Wildlife and Sport Fish Restoration
Programs Improvement Act of 2000,
AFWA submits a list of projects to us
each year to consider for funding under
the Multistate Conservation Grant
program. We then review and award
grants from this list.
ADDRESSES: John C. Stremple, Multistate
Conservation Grants Program
Coordinator, Division of Federal
Assistance, U.S. Fish and Wildlife
Service, 4401 North Fairfax Drive, Mail
Stop MBSP–4020, Arlington, Virginia
22203.
FOR FURTHER INFORMATION CONTACT: John
C. Stremple, (703) 358–2156 (phone) or
John_Stremple@fws.gov (e-mail).
SUPPLEMENTARY INFORMATION: The
Wildlife and Sport Fish Restoration
Programs Improvement Act of 2000
(Improvement Act, Pub. L. 106–408)
amended the Pittman-Robertson
Wildlife Restoration Act (16 U.S.C. 669
et seq.) and the Dingell-Johnson Sport
Fish Restoration Act (16 U.S.C. 777 et
seq.) and established the Multistate
Conservation Grant Program. The
Improvement Act authorizes us to
award grants of up to $3 million
annually from funds available under
each of the Restoration Acts, for a total
of up to $6 million annually. We may
award grants from a list of priority
projects recommended to us by AFWA.
The FWS Director, exercising the
E:\FR\FM\21FEN1.SGM
21FEN1
Agencies
[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Page 9582]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-3162]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Regulatory Approved
Clinical Diagnostics for Anti-HPV16 L1 Serum Antibody Detection in HPV
Vaccine Recipients
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive worldwide license to practice the invention embodied in
HHS Ref. No. E-253-1993/0 and certain foreign rights under HHS Ref. No.
E-166-1992 including U.S. Patent 5,437,951, U.S. Patent 5,985,610, U.S.
Patent 5,871,998, U.S. Patent 5,716,620, U.S. Patent 5,744,142, U.S.
Patent 5,756,284, U.S. Patent 5,709,996, U.S. Patent Application 09/
316,487, U.S. Patent Application 10/371,846, International Patent
Application PCT/US93/08342, European Patent Application 93921353.4,
European Patent Application 040104531.1, European Patent Application
040783235, Australian Patent 683220, Australian Patent Application
2004203609, Canadian Patent No. 2,143,845, Japanese Patent Applications
1994-507481, Japanese Patent Applications 2001-101791 and continuation
and divisional patents and patent applications thereof, entitled
``Self-Assembling Recombinant Papillomavirus HPV16 Capsid Proteins,''
to Biotrin International, Ltd., a limited liability company formed
under the laws of the European Union and the Republic of Ireland. The
United States of America is the assignee of the patent rights of the
above inventions.
The contemplated exclusive license may be granted in the field of
regulatory approved clinical diagnostics for serum anti-HPV16 L1
antibody detection in HPV vaccine recipients.
DATE: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before April 21, 2008
will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Michael A. Shmilovich, Esq., Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5019; Facsimile: (301) 402-0220; E-mail: shmilovm@mail.nih.gov. A
signed confidentiality nondisclosure agreement may be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: The patent applications intended for
licensure disclose and/or cover the following:
E-253-1993 and E-166-1992, ``Self-Assembling Recombinant
Papillomavirus Capsid Proteins of HPV16,'' Lowy et al.
Recombinant human papillomavirus 16 capsid proteins that are
capable of self-assembly into capsomer structures and viral capsids
that comprise conformational antigenic epitopes. The capsomer
structures and viral capsids, consisting of the capsid proteins that
are expression products of a bovine, monkey or human papillomavirus L1
conformational coding sequence proteins, can be prepared for use in
ELISA or cell-based immunoassays for detecting the level of serum
antibody in recipients of a vaccine against HPV16. The self-assembling
capsid proteins can also be used as elements of diagnostic immunoassay
procedures for papillomavirus infection.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within sixty
(60) days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: February 14, 2008.
David Sadowski,
Deputy Director, Division of Technology Development and Transfer,
Office of Technology Transfer, National Institutes of Health.
[FR Doc. E8-3162 Filed 2-20-08; 8:45 am]
BILLING CODE 4140-01-P